

CLEAN VERSION OF AMENDED CLAIMS - 0480/001210

4. The process as claimed in claim 1, where those compounds are read out whose  $K_i$  value for binding to 5-HT<sub>5</sub> receptors is also less than  $10^{-8}$  M.
5. The process as claimed in claim 1, where also at least one 5-HT<sub>5</sub> binding partner-induced action is determined.
7. The process as claimed in claim 5, where the binding of GTP to G proteins, intracellular calcium levels, the phospholipase C activity and/or the cAMP production are determined.
8. The process as claimed in claim 1, where, for determining binding affinity and/or activity, the compounds are brought into contact with cellular systems having 5-HT<sub>5</sub> receptors.
14. The use as claimed in claim 11, where the  $K_i$  value for binding of the binding partner to 5-HT<sub>5</sub> receptors is less than  $10^{-8}$  M.
15. The use as claimed in claim 1, where the binding partner is a 5-HT<sub>5</sub> agonist.
16. The use as claimed in claim 11, for the treatment of migraine.

09/869814-47369350